Breakthrough in Cancer Gene Mutation Detection: 454 Sequencing Revolutionizes Personalized Medicine

Strategic Insights -

454 Life Sciences Corporation, a majority-owned subsidiary of CuraGen Corporation, in collaboration with scientists at Dana Farber Cancer Center and Broad Institute, has reported a new method for the detection of cancer gene mutations present at extremely low levels. This research, published in the journal Nature Medicine, describes how the 454 Sequencing method identifies rare cancer-associated genetic variations at the molecular level, enabling the personalization of targeted therapies. The technology has the potential to validate the ability of EGFR mutations to predict patient responsiveness to treatment with an EGFR inhibitor.

Key Takeaways:

  • The 454 Sequencing method detects cancer gene mutations present at extremely low levels, enabling personalized medicine.
  • The technology identifies rare cancer-associated genetic variations at the molecular level, potentially predicting patient responsiveness to treatment with an EGFR inhibitor.
  • 454 Sequencing technology was used to analyze mutations in five exons of the EGFR gene in tumor samples from 22 patients with lung cancer.
  • The EGFR gene is the target for several new anti-cancer drugs called EGFR inhibitors, and the research proposes that 454 Sequencing may help to validate the ability of EGFR mutations to predict patient responsiveness to treatment.
  • 454 Sequencing is the first advanced sequencing technology that can generate hundreds of thousands of DNA sequences in one run, rapidly and comprehensively conducting high-throughput nucleotide sequencing.
  • The technology may be used to detect cancer-associated genetic mutations in medical research settings, enabling accurate molecular diagnosis of heterogeneous cancer specimens and patient selection for targeted cancer therapies.
  • Dr. Matthew Meyerson, senior author of the study, explained that "Analysis of DNA from tumors is complicated by varying amounts of tumor cells in patient samples, and 454 Sequencing may facilitate accurate molecular diagnosis of heterogeneous cancer specimens and enable patient selection for targeted cancer therapies."

Statistics:

  • The 454 Sequencing method generates hundreds of thousands of DNA sequences in one run, making it a high-throughput technology.
  • The PicoTiterPlate allows a single instrument to produce over 20 million nucleotide bases per five-hour run, totaling more than 60 times the capacity of instruments using current macro-scale technology.
  • The technology has the potential to enable personalized medicine, including identifying the early stages of drug resistance and facilitating a change in treatment tailored to a patient's unique genetic response.

Sources:

  • Research paper published in Nature Medicine
  • Dana Farber Cancer Center and Broad Institute
  • 454 Life Sciences Corporation
  • CuraGen Corporation
  • Health & Medicine Week via NewsRx.com